|

Sacituzumab Govitecan (SG) Clinical Trials

8 actively recruiting trials across 5 locations

Also known as: GS-0132, IMMU 132, IMMU-132, Sacituzumab Govitecan-hziy, Trodelvy, Trodelvy®

Other3 trials

Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study
Sacituzumab Govitecan in Metastatic Colorectal Cancer
Phase 2/3
Trop-2 Targeted PET Probes in Advanced TNBC
N/A

Anaheim, California1 trial

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Los Angeles Cancer Network

Phase 3

Los Angeles, California1 trial

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

USC Norris Comprehensive Cancer Center

Phase 1/2

Orange, California1 trial

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence

Chao Family Comprehensive Cancer Center, University of California, Irvine

Phase 2

New Haven, Connecticut1 trial

Saci Nivo Rela for TNBC

Yale University

Phase 1/2

Boston, Massachusetts1 trial

Sacituzumab Govitecan Plus EV in Metastatic UC

Dana Farber Cancer Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.